Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: AGIO

Agios Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for AGIO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-7.02

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:47 UTC.

What Agios Pharmaceuticals, Inc. does

This company is a commercial-stage biopharmaceutical firm focused on rare disease treatment, particularly in hematology. Its lead product, mitapivat, is approved in multiple regions under the brand names PYRUKYND and AQVESME for treating various forms of anemia and thalassemia. The company also develops other candidates including tebapivat for myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236, an in-licensed siRNA therapy for polycythemia vera.

Summarized from Agios Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-7.02

Revenue, margins & earnings

FY2022: net loss $232M on revenue $14M$14MFY2022FY2023: net loss $352M on revenue $27M$27MFY2023FY2024 Revenue: $36M — margin split not shown (non-operating gains)FY2024: net income $674M exceeded revenue $36M by $637M — non-operating gains (e.g. asset sales), not operating profit$36MFY2024FY2025: net loss $413M on revenue $54M$54MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-06
  • 2026-08-06Chief Medical OfficerSale-30,000$914.4K
  • 2026-07-10DirectorAward1,447—
  • 2026-07-10DirectorRestricted stock unitsOption exercise-1,447—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Agios Pharmaceuticals, Inc. do?

This company is a commercial-stage biopharmaceutical firm focused on rare disease treatment, particularly in hematology.

When did AGIO last file with the SEC?

Agios Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:47 UTC. This page is also available as JSON at /api/data?ticker=AGIO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AGIO and 5,000+ tickers.

Create a free account — keep AGIO
For your agent
GET /api/data?ticker=AGIO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt